Live tv
search
  1. You Are At:
  2. English News
  3. India
  4. Coronavirus vaccination in India may start in January, expect normal life by October: Adar Poonawalla

Coronavirus vaccination in India may start in January, expect normal life by October: Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Sunday said the COVID-19 vaccination drive in the country was likely to begin by January, in line with expectations of receiving approvals for emergency-use authorisation of Oxford-AstraZeneca vaccinate candidate by month-end.

India TV News Desk Edited by: India TV News Desk New Delhi Updated on: December 13, 2020 16:26 IST
Coronavirus vaccination in India may start in January,
Image Source : FILE IMAGE

Coronavirus vaccination in India may start in January, expect normal life by October: Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Sunday said the COVID-19 vaccination drive in the country was likely to begin by January, in line with expectations of receiving approvals for emergency-use authorisation of Oxford-AstraZeneca vaccinate candidate by month-end. 

 
Speaking at The Economic Times Global Business Summit, Adar Poonawalla said he expected everyone in India to be vaccinated by October 21 and that normal life could return soon after. “By this month-end, we might get an emergency licence [for the coronavirus vaccine], but the actual licence for wider use might come in at a later date. But we are confident that if the regulators give a nod, India’s vaccination drive can start by January 2021,” Adar Poonawalla said.

“Once 20% of India gets the coronavirus vaccine, we can hopefully see the confidence and sentiments coming back, and by September-October next year hopefully there will be enough vaccines for everyone and normal life can return,” he said.

Earlier on December 7, the vaccine major had applied to the Drugs Controller General of India (DCGI) for emergency use authorisation for AstraZeneca-Oxford COVID-19 vaccine in the country. According to the Indian Council of Medical Research (ICMR), SII has already manufactured 40 million doses of the vaccine under the at-risk manufacturing and stockpiling license it obtained from the DCGI.

An expert committee of the Central Drugs Standard Control Organisation (CDSCO) sought additional safety and efficacy data for coronavirus vaccine candidates of Serum and Bharat Biotech after deliberating upon their applications seeking emergency use authorisation for their shots. 

READ MORE: Oxford-AstraZeneca in ‘mix-match’ COVID-19 vaccine trial with Russia’s Sputnik

READ MORE: Covid-19 vaccine: Initial doses of Pfizer to begin from December 14 in US

RELATED VIDEO

Latest India News